ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress
May 22 2015 - 7:35AM
Business Wire
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
today announced that clinical data on Iclusig® (ponatinib) will be
presented at the 20th conference of the European Hematology
Association (EHA) being held in Vienna, Austria, June 11 to 14,
2015.
The schedule and meeting location for the sessions, together
with the abstract information, are listed below:
Title:
Ponatinib Efficacy and Safety in
Heavily Pretreated Leukemia Patients: 3-Year Results of the PACE
Trial
Abstract No: P234 Presenter: Jorge Cortes, M.D., (The University of
Texas MD Anderson Cancer Center, Houston, US) Poster Session:
Chronic myeloid leukemia – Clinical 1 Date & Time: Friday, 12
June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C
Title:
Long-Term Follow-up of Ponatinib
Efficacy and Safety in Patients (Pts) with the T315I Mutation in
the Phase 1 and Phase 2 (PACE) Trials
Abstract No: P236 Presenter: Michele Baccarani, M.D., (University
of Bologna, Italy) Poster Session: Chronic myeloid leukemia -
Clinical 1 Date & Time: Friday, 12 June, 2015, 17:15 – 18:45
(CEST) Location: Poster Area, Hall C
Title:
Minimum Follow-up of 4 Years for
Ongoing Patients with Chronic-Phase Chronic Myeloid Leukemia
(CP-CML) in a Phase 1 Trial of Ponatinib
Abstract No: P237 Presenter: Moshe Talpaz, M.D., (University of
Michigan Medical Center, Ann Arbor, US) Poster Session: Chronic
myeloid leukemia – Clinical 1 Date & Time: Friday, 12 June,
2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C
Title:
Responses at Early Landmark Time Points
are Associated with Outcomes in Heavily Pretreated CP-CML Patients
(Pts) Treated with Ponatinib
Abstract No: P235 Presenter: Martin C. Müller, M.D. (Medical
Clinic, University Hospital Mannheim, Mannheim, Germany) Poster
Session: Chronic myeloid leukemia – Clinical 1 Date & Time:
Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area,
Hall C Title:
A Model-Based Assessment of the
Benefits and Risks of Ponatinib Versus Bosutinib in Third-Line
Treatment of Chronic Myeloid Leukemia (CP-CML)
Abstract No: P424 Presenter: Shannon Cartier, M.D., (Optum,
Burlington, Canada) Oral Session: Quality of life, palliative care,
ethics and health economics Date & Time: Friday, 12 June, 2015,
17:15 – 18:45 (CEST) Location: Poster Area, Hall C
About Iclusig® (ponatinib) tablets
Iclusig is approved in the U.S., EU, Switzerland, Australia,
Israel and Canada. Iclusig is a kinase inhibitor indicated in the
EU for adult patients with:
- chronic phase, accelerated phase, or
blast phase chronic myeloid leukemia (CML) who are resistant to
dasatinib or nilotinib; who are intolerant to dasatinib or
nilotinib and for whom subsequent treatment with imatinib is not
clinically appropriate; or who have the T315I mutation
- Philadelphia chromosome positive acute
lymphoblastic leukaemia (PH+ ALL) who are resistant to dasatinib;
who are intolerant to dasatinib and for whom subsequent treatment
with imatinib is not clinically appropriate; or who have the T315I
mutation.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts and Lausanne, Switzerland, is an integrated global
oncology company focused on transforming the lives of cancer
patients with breakthrough medicines. ARIAD is working on new
medicines to advance the treatment of various forms of chronic and
acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer
medicines. For additional information, visit
http://www.ariad.com or follow ARIAD on Twitter
(@ARIADPharm).
Iclusig® is a registered trademark of ARIAD Pharmaceuticals,
Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150522005100/en/
ARIAD PharmaceuticalsFor InvestorsKendra Adams,
617-503-7028Kendra.adams@ariad.comorFor U.S. MediaLiza
Heapes, 617-621-2315Liza.heapes@ariad.comorFor EU MediaGemma
White, +44 (0)20 337 25 221gwhite@biosector2.co.uk
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Apr 2023 to Apr 2024